Curaleaf Issues Statement Regarding Alternative Proposal for Aurora Cannabis

Curaleaf publicly acknowledged Aurora's announcement of an alternative transaction with Organigram while stressing that Curaleaf's enhanced tender offer, first made August 18 and improved October 6, remains outstanding for all Aurora common shares. Curaleaf argues its offer delivers better value, greater certainty and speed to close, and larger synergies, and faulted Aurora and Organigram for withholding material details such as any break fee, management composition, and investor rights granted to BAT.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.